← Back to patent-cliff list
Alfosbuvir
Tier C — Watch / tradeAlfosbuvir
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NS5B
Indications (approved)：Chronic hepatitis C
Regional status
US
-
EU
-
China
Approved
2023-05-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Alfosbuvir?
Approved indications include: Chronic hepatitis C.
When does the Alfosbuvir patent expire?
No public expiry year is available for Alfosbuvir yet; this page updates once verified.
How do I get a quote for Alfosbuvir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27